HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery.

Abstract
Bone marrow stem cells are able to repair infarcted human myocardium following intracoronary transplantation via the infarct-relative artery. However, traditional reperfusion strategies fail to open the artery in some patients, making effective delivery impossible. Our previous study demonstrated a safe and efficient approach to delivering bone marrow stem cells via a noninfarcted artery in an animal myocardial infarction model. The objective of the present study was to evaluate the safety and feasibility of autologous bone marrow mesenchymal stem cell transplantation via such an approach in patients with acute myocardial infarction (AMI). Sixteen patients with anterior AMI who had successfully undergone percutaneous coronary intervention (PCI) were enrolled in this pilot, randomized study. Three weeks after PCI, cultured bone marrow mesenchymal stem cells were injected into the myocardium via either the infarct-relative artery (left anterior descending branch artery, LAD) or a noninfarct-relative artery (right coronary artery, RCA). The safety and feasibility of the cell infusion were evaluated during the procedure and during 6 months of follow-up. In addition, 2D echocardiography, technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) and 18F-deoxyglucose single photon emission computed tomography were employed to examine cardiac function, myocardial perfusion, and viable cardiomyocytes, respectively, at day 4 after PCI and 6 months after the cell infusion. There were no arrhythmia and any other side-effects, including infections, allergic reactions or adverse clinical events, during, immediately after, or 6 months after cell transplantation. Cardiac function and myocardial perfusion had improved 6 months after PCI/bone marrow stem cells transplantation. Viable cardiomyocytes metabolism was detected in the infarcted areas in both groups after the cell infusion, as demonstrated by 18F-deoxyglucose. Intracoronary infusion of autologous bone marrow mesenchymal stem cells via a noninfarct-relative artery appears safe and feasible in the treatment of patients with AMI.
AuthorsZhijian Yang, Fumin Zhang, Wenzhu Ma, Bo Chen, Fang Zhou, Zhaoqiang Xu, Yuqing Zhang, Dingguo Zhang, Tiebing Zhu, Liansheng Wang, Hui Wang, Zhijian Ding, Yuyan Zhang
JournalCardiovascular therapeutics (Cardiovasc Ther) Vol. 28 Issue 6 Pg. 380-5 (Dec 2010) ISSN: 1755-5922 [Electronic] England
PMID20337639 (Publication Type: Journal Article, Randomized Controlled Trial)
Copyright© 2010 Blackwell Publishing Ltd.
Topics
  • Aged
  • Angioplasty, Balloon, Coronary
  • Anterior Wall Myocardial Infarction (metabolism, pathology, physiopathology, therapy)
  • Bone Marrow Transplantation (methods)
  • Cell Survival
  • Cells, Cultured
  • China
  • Coronary Circulation
  • Echocardiography
  • Feasibility Studies
  • Humans
  • Mesenchymal Stem Cell Transplantation (methods)
  • Middle Aged
  • Myocardial Perfusion Imaging
  • Myocardium (metabolism, pathology)
  • Myocytes, Cardiac (metabolism, pathology, transplantation)
  • Pilot Projects
  • Recovery of Function
  • Regeneration
  • Stroke Volume
  • Time Factors
  • Tomography, Emission-Computed, Single-Photon
  • Treatment Outcome
  • Ventricular Function, Left

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: